Allergy Therapeutics (AGY)

 

AGY Share PerformanceMore

52 week high39.50 10/10/17
52 week low19.50 12/12/16
52 week change 11.50 (44.66%)
4 week volume7,452,823 23/09/17

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Publication of Annual Report and notice of AGM

RNS Number: 1267U Allergy Therapeutics PLC 19 October 2017 19 October 2017 Allergy Therapeutics plc ("Allergy Therapeutics" or the "Company") ANNUAL FINANCIAL REPORT 2017 AND NOTICE OF 2017 ANNUAL GENERAL MEETING Allergy Therapeutics Plc has today published the following documents: Annual Report for the year ended 30 June 201...

Allergy Therapeutics starts dosing for grass pollen trial

Allergy Therapeutics has started its G205 phase II study designed to evaluate the dose-response and safety of its ultra-short c...

Commencement of dosing in PQ Grass Phase II Trial

RNS Number: 0102U Allergy Therapeutics PLC 19 October 2017 Allergy Therapeutics plc ("Allergy Therapeutics" or the "Group") Commencement of dosing in PQ Grass Phase II Trial 19 October 2017 Allergy Therapeutics plc (AIM:AGY), the fully integrated specialty pharmaceutical group specialising in allergy vaccines, today announces that dosing has commenced i...

Holding(s) in Company

RNS Number: 4959T Allergy Therapeutics PLC 12 October 2017 TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: Allergy The...

Director Deals - Allergy Therapeutics PLC (AGY)

Dr Tunde Otulana, Non Executive Director, bought 25,000 shares in the company on the 11th October 2017 at a price of 38.4...

Director/PDMR Shareholding

RNS Number: 4794T Allergy Therapeutics PLC 12 October 2017 12 October 2017 Allergy Therapeutics plc ("Allergy Therapeutics" or the "Company") Director/PDMR Shareholding Allergy Therapeutics (AIM:AGY) , the fully integrated specialty pharmaceutical company specialising in allergy vaccines, announces that, on 11 October 2017, Tunde Otulana, Non-Executiv...

Allergy Therapeutics 'continuing to gain market share'

Hardman Research has issued a report on Allergy Therapeutics which highlights the company's continuing gain in market...

Hardman Research: Continuing to gain market share

RNS Number: 1249T Allergy Therapeutics PLC 10 October 2017 Hardman Research: Continuing to gain market share Continuing to gain market share - AGY is a long-established specialist in the prevention, diagnosis and treatment of allergies. Pollinex Quattro continues to gain market share despite being available in the EU only on a 'Named Patient' basis. Investment ...

Fundamental DataMore

EPS-0.42
Dividend yield0 %

Latest discussion posts More

  • Re: Excellent Volume

    Harman although I like the sound of Hardpan Research. I could have done with some of that many times in investments made!!
    10-Oct-2017
    Chicken Lips
  • Excellent Volume

    Excellent volume today. The hardpan research or maybe AGY is beginning to be noticed with its excellent product and product pipeline. CL
    10-Oct-2017
    Chicken Lips
  • Chart

    Looking promising. Break above consolidation to form a new ten year high. Price closed well above the upper band with the bands expanding. All averages aligned. ...
    8-Oct-2017
    penhome

Users' HoldingsMore

Users who hold Allergy Therapeutics also hold..
LLOYDS GRP.27%
BP23%
VODAFONE GRP.16%
BT GROUP16%
NATIONAL GRID16%

Codes & Symbols

ISINGB00B02LCQ05
SymbolsAGY, LSE:AGY, AGY.L, AGY:LN, LON:AGY, XLON:AGY